Platelet Function in Resuscitated Patients

Medical University of Graz

Status: Completed

Conditions: Acute ST Segment Elevation Myocardial Infarction

Treatments: Other: diagnostic analysis of platelet function

Study type: Observational

Funder types: Other

Identifiers

NCT02914795

27-290ex14/15

Details and patient eligibility

About

Approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due to myocardial infarction. Almost all patients are initially diagnosed and treated in the cath lab. Therapy usually consists of one or more stent implantations. After implantation of a coronary stent, dual platelet inhibition is necessary for 12 months. Insufficient platelet inhibition causes an pronounced increase in risk of stent thrombosis. Therefore, knowledge of the individual platelet function is valuable.

Several factors potentially promote a delayed or reduced mode of action of platelet function inhibitors in resuscitated patients:

1. oral administration is impossible and medication needs to be administered via a gastric line.
2. gastric absorption is delayed after resuscitation
3. according to current guidelines patients are treated with therapeutic hypothermia. Including the time of rewarming cooling period is ~48h

Full description

Patients after successful resuscitation associated to a myocardial infarction will be included into the study the morning after the index event. Patients get dual platelet inhibition at the discretion of the interventionist. Patients are treated with therapeutic hypothermia according to the local Standard operating procedure for 24h and rewarming is performed within an additional 20h. Platelet function is measured every morning and Aspirin mediated as well as P2Y12 (purinergic G protein-coupled receptors-12)-inhibition mediated platelet function inhibition is recorded. All relevant clinical data including APACHE (Acute Physiology and Chronic Health Evaluation) and SOFA ( Sequential Organ Failure Assessment score) scores are collected.

The degree of platelet inhibition over time (7 days) and differences between the three drugs tested will be evaluated by optical aggregometry and by using the commercial VerifyNow test system.

Enrollment: 99 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Myocardial infarction
• dual platelet inhibition
• resuscitation
• therapeutic hypothermia

Exclusion criteria

• none

Trial design

99 participants in 2 patient groups

non-resuscitated myocardial infarction

Description:

diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial

Treatment:

Other: diagnostic analysis of platelet function

resuscitated myocardial infarction

Description:

diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria

Treatment:

Other: diagnostic analysis of platelet function